铜化重定向中性粒细胞功能,以增强神经母细胞瘤中的抗GD2抗体治疗
Jourdin R C Rouaen1,2, Antonietta Salerno1,2, Tyler Shai-Hee1,2
1School of Biomedical Sciences, UNSW Medicine & Health, UNSW Sydney, Sydney, NSW, Australia.
Nature communications
|December 12, 2024
概括
铜化增强了神经母细胞瘤的抗-disialoganglioside (GD2) 抗体疗法,通过启动瘤微环境. 这种策略增强了中性粒细胞的抗瘤活性,提供了潜在的新治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 对神经母细胞瘤而言,抗迪沙龙化 (GD2) 抗体疗法是有前途的,但由于免疫抑制瘤微环境而面临局限性.
- 内铜水平与神经母细胞瘤中的免疫逃避有关.
研究的目的:
- 调查铜化是否可以在神经母细胞瘤模型中强化抗GD2抗体治疗.
- 阐明铜化影响瘤免疫微环境和抗瘤免疫的机制.
主要方法:
- 利用了免疫能力强的神经母细胞瘤模型.
- 与抗GD2抗体疗法一起使用辅助性化铜.
- 进行了评估免疫细胞透,活性和功能的机制研究.
- 评估了临床批准的铜合剂Cuprior的疗效.
主要成果:
- 辅助铜化显著增强了抗GD2抗体疗法,导致持久的瘤控制.
- 铜化促进了免疫原料瘤微环境,通过增加Fc受体携带细胞的透和活动,特别是中性粒细胞.
- 经过神经母细胞瘤的铜封存被证明会损害中性粒细胞的功能,而这种功能被铜化反转,增强了促炎功能.
结论:
- 铜化是一种有效的免疫调节策略,可增强神经母细胞瘤中抗GD2抗体治疗的效果.
- 重新利用铜合剂Cuprior提供了一种无毒的方法来增强抗瘤免疫力.
- 这些发现支持对Cuprior作为辅助疗法的临床研究,以改善神经母细胞瘤患者的治疗结果.
更多相关视频
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.2K
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.3K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K